Cargando…

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pre-existing CXCR4-using virus or through selection of CCR5-tropic resistant virus, characterized by plat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jubb, Becky, Lewis, Marilyn, McFadyen, Lynn, Simpson, Paul, Mori, Julie, Chan, Phylinda, Weatherley, Barry, van der Ryst, Elna, Westby, Mike, Craig, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931239/ https://www.ncbi.nlm.nih.gov/pubmed/31856576 http://dx.doi.org/10.1177/2040206619895706

Ejemplares similares

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
por: Lewis, ME, et al.
Publicado: (2021)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
por: Jacqmin, P, et al.
Publicado: (2013)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects
por: Chan, Phylinda L. S., et al.
Publicado: (2010)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials
por: Lewis, Marilyn, et al.
Publicado: (2018)

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
por: Lewis, ME, et al.
Publicado: (2021)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
por: Jiang, Xiaowei, et al.
Publicado: (2015)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
por: Roche, Michael, et al.
Publicado: (2013)

Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
por: Valdez, H, et al.
Publicado: (2010)

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018)

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis
por: Weatherley, Barry, et al.
Publicado: (2017)

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

Pregabalin Population Pharmacokinetic and Exposure‐Response Analyses for Focal Onset Seizures in Children (4–16 years) and Adults, to Support Dose Recommendations in Children
por: Chan, Phylinda L. S., et al.
Publicado: (2021)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
por: Harms, Mirja, et al.
Publicado: (2023)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth
por: Casagrande, Naike, et al.
Publicado: (2019)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

Growth potentials of CCR5-tropic/CXCR4-tropic HIV-1mt clones in macaque cells
por: Doi, Naoya, et al.
Publicado: (2013)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index
por: dos Santos, Monika ML, et al.
Publicado: (2014)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

HIV-1 Tropism Dynamics and Phylogenetic Analysis from Longitudinal Ultra-Deep Sequencing Data of CCR5- and CXCR4-Using Variants
por: Sede, Mariano M., et al.
Publicado: (2014)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2019)

CXCR4- and CCR5-Tropic HIV-1 Clones Are Both Tractable to Grow in Rhesus Macaques
por: Doi, Naoya, et al.
Publicado: (2018)

Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1
por: Itell, Hannah L., et al.
Publicado: (2023)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
por: Despiegel, Nicolas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_il4b6ihia0f30ta1gqebrvftg1